Signals, Powered By EquityPandit
The governmental body Department of Pharmaceuticals taking a big decision towards anti-cancer drugs has announced to puts a cap on trade margin of 30 per cent and has directed directs manufacturers to fix their retail price based on the price at first point of sale of the product of the non-scheduled formulations containing any of the 42 drugs.
The DoP in its statement said that the National Pharmaceutical Pricing Authority has invoked extraordinary powers in public interest, under para 19 of the Drugs (Prices Control) Order, 2013 to bring 42 non-scheduled anti-cancer drugs under price control through trade margin rationalisation.
Now as per data available with NPPA, the MRP for 105 brands will be reduced up to 85 per cent entailing minimum saving of Rs 105 crore to consumers. As of now, 57 anti-cancer drugs are already under price control as scheduled formulations.
The notification also said, “These [new drugs under price control] would cover 72 formulations and 355 brands as per data available with NPPA. More data is being collected from hospitals and manufacturers to finalise the list.”
Seven days of the time period has been granted to drug manufacturers to recalculate the prices and inform the NPPA, state drug controllers, stockists and retailers. The revised prices shall come into effect from March 8.
